Papers/PMID:41630017
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study.
BMC medicine2026The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
selenium atom — no detected effect on health-related quality of life
Evidence strength: moderate.FindingNull resultreplicated ×1“No statistically significant difference in the EORTC QLQ-C30 summary score was found between the experimental and control groups over time (Additional file 1: Table S1).”
Quoted verbatim from Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study.. - Study
- RCT
- Dose
- sodium selenite pentahydrate 2000 ug/40 mL intravenously over two hours before each chemotherapy cycle, six cycles every 3 weeks
- Population
- patients with platinum-sensitive recurrent ovarian cancer receiving paclitaxel, carboplatin and bevacizumab in both arms; selenium arm against intravenous normal saline placebo, group-by-time repeated-measures ANOVA
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study.2026PMID:4163001710.1186/s12916-026-04637-xIndustry fundedPermalink